All In Biotech

Drug Trial Radar · NCT06489808

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

An Open-label, Multicenter, Multi-cohort Clinical Study of Linperlisib Combined With Standard Immunochemotherapy in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma Failing to First-line Therapy

Last checked: Nov 20, 2026Latest source record: Jul 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

89

Planned (sponsor's estimate)

Start

May 28, 2024

Primary completion

Dec 31, 2026

Study completion May 31, 2027

Sponsor

Lead sponsor
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of Linperlisib combined with standard immunochemotherapy in patients with R/R LBCL.

Conditions

  • Relapsed/Refractory Large B-Cell Lymphoma

Interventions

  • LinperlisibDrug

    Linperlisib RP2D D1-14

  • RituximabDrug

    rituximab 375 mg/m2 D0

  • GemcitabineDrug

    gemcitabine per regimen dosage

  • OxaliplatinDrug

    Oxaliplatin 130 mg/m2 D1

  • IfosfamideDrug

    Ifosfamide 5g/m2 D2

  • CarboplatinDrug

    Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)

  • EtoposideDrug

    Etoposide 100mg/m2 D1-3

  • DexamethasoneDrug

    Dexamethasone 40mg D1-4

  • CisplatinDrug

    Cisplatin 100mg/m2 D1, continuous intravenous infusion

  • Ara-CDrug

    Ara-C 2g/m2 q12h D2

  • VinorelbineDrug

    Vinorelbine 20mg/m2 D1

  • Mitoxantrone hydrochloride liposomeDrug

    Mitoxantrone hydrochloride liposome 18mg/m2 D1

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-Limiting ToxicitiesTime frame: Safety Run-in Period, up to the end of cycle 1 (each cycle is 21 days)
  2. ORRTime frame: up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Disease Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.